Nectar is building a comprehensive, vertically integrated allergy healthcare platform that leverages data and clinical research to offer a personalized, patient-centric approach to allergy care. Led by founder and CEO Kenneth Chahine, Nectar is the direct-to-consumer brand developed by Nectar Life Sciences.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/20/22 | $16,500,000 | Series A |
Harmony Partners Juxtapose Obvious Ventures | undisclosed |
